Loading...
Loading...
Ascendis Pharma A/S
Ascendis Pharma A/S. Spoken Alpha tracks ASND's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks ASND's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 8/10 quarters but stock falls 90% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Missed in 2 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ASND.
curl https://api.spokenalpha.com/v1/companies/ASND| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $1.60 | $1.58 | +1.3% | -2.8% | -5.6% |
| Q4 FY2026 | $1.49 | $1.54 | -3.1% | -4.4% | -7.4% |
| Q3 FY2026 | $1.32 | $1.38 | -4.1% | -4.6% | -1.8% |
| Q2 FY2026 | $1.49 | $1.41 | +5.6% | -2.8% | -5.2% |
| Q1 FY2025 | $1.56 | $1.53 | +1.9% | -4.8% | -4.1% |
| Q4 FY2025 | $1.53 | $1.50 | +2.0% | -8.7% | -8.4% |
| Q3 FY2025 | $1.78 | $1.70 | +4.8% | -6.7% | -9.3% |
| Q2 FY2025 | $1.85 | $1.74 | +6.4% | -0.5% | -2.9% |
| Q1 FY2024 | $1.61 | $1.57 | +2.7% | +1.2% | +3.8% |
| Q4 FY2024 | $1.64 | $1.57 | +4.7% | -3.0% | -3.0% |